PharmaIN

Executive Summary

PharmaIN is a clinical-stage biopharmaceutical company pioneering first- and best-in-class subcutaneous therapies through thoughtful peptide engineering. Based in San Diego, the company leverages its expertise in target-specific biology, peptide drug design, and innovative drug delivery to develop novel treatments for patients with advanced liver cirrhosis and cancer. Founded in 2018, PharmaIN is currently in Phase 1 development, focusing on addressing significant unmet medical needs in these disease areas. Its approach aims to improve patient outcomes by enhancing drug stability, bioavailability, and convenience through subcutaneous administration, potentially reducing the burden on healthcare systems.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for lead candidate in liver cirrhosis60% success
• Q2 2027IND filing for second candidate in oncology50% success
• H1 2027Partnership or collaboration announcement for peptide delivery platform70% success